Inflammatory bowel disease (IBD) is multifaceted and diverse in its classification. IBD's global prevalence has grown every year, significantly reducing the quality of life for individuals, and increasing the economic burden for governments. At Protheragen, we have a range of services geared specifically toward the needs of researchers and drug companies focused on developing novel therapeutics for IBD.

Introduction to Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease (IBD) encompasses a multitude of conditions such as Crohn's disease and ulcerative colitis which, inflame the gastrointestinal tract. These two conditions tend to flare up episodically presenting as diarrhea, abdominal pain, fatigue, and in some cases, even considerable weight loss. The classification of Crohn's disease or ulcerative colitis is largely defined based on disease location and to a smaller extent histological appearances. While ulcerative colitis is denoted by continuous superficial inflammation of the colon and rectum, Crohn's disease features intestinal skip lesions with transmural inflammation anywhere in the gastrointestinal tract.

Fig.1 Management aspects in paediatric-onset IBD. (Ashton, J. J., and Beattie, R. M. 2024)

Pathogenesis of Inflammatory Bowel Disease (IBD)

Dissecting the biological mechanisms behind IBD is a work in progress; however, it is largely accepted that a combination of the environment, genetics, immune response, and microorganisms causes IBD.

Fig.2 Disease etiology in IBD. (Ashton, J. J., and Beattie, R. M. 2024)

Therapeutics Development for Inflammatory Bowel Disease (IBD)

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Use contemporary technologies and techniques to optimize the research and development process. Our professionals are committed to your assistance at all levels of the drug development process from primary research and preclinical studies, to provide one-stop research services including diagnostic and therapeutic development services. Moreover, we also offer services for customized disease model development which enable comprehensive research of factors involved in the development of IBD from genetic, environmental, and immune perspectives.

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services

Animal models for IBD serve as the basis for carrying out research and developing new drugs for this multifaceted illness. These models are invaluable for studying the causes of IBD, trying out new therapeutics, and measuring their effects within an experimental environment. We are committed to providing animal model development services of IBD for revolutionary work on IBD therapies in pharmaceutical research.

Chemical-induced Model

The model based on chemicals uses TNBS, DSS, or oxazolone administered to animals to simulate the progression of IBD.

• TNBS-induced model
• Oxazolone-induced model
• DSS-induced model

Genetically Engineering Model

Some models of IBD pathogenesis-related features were created through genetic engineering modification.

• Iκκ-γ (NEMO) deficiency model
• IL-10 deficiency model

T-Cell Adoptive Transfer Model

The infusion of CD45RB^highCD4⁺ T cells from healthy mice into SCID mice led to heightened inflammatory responses, to replicate the role of immune cells in IBD.

• CD4⁺ T-cell transfer model

Understanding the demanding challenges that arise from conducting research IBD, Protheragen proffers tailor-made services that achieve your unique research goals. Be it efficacy testing, pharmacokinetic studies, or drug safety evaluation, we can provide you with exceed supports. Reach out to us today to find out how we can assist your research efforts and support the development of innovative therapies.

Reference

• Ashton, James John, and R Mark Beattie. "Inflammatory bowel disease: recent developments." Archives of disease in childhood 109.5 (2024): 370-376.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.